The Food and Drug Administration approved Johnson & Johnson's nasal spray to be used alone in adults with a major depressive disorder that is difficult to treat, as sales of the drug grow.

Johnson & Johnson's Spravato was approved to treat a major depressive disorder, or MDD, in adults. The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat ...

FDA Approves Johnson & Johnson’s IMAAVYTM (nipocalimab-aahu) a New Treatment for Myasthenia Gravis (MG), Offering Hope for Families Provided by GlobeNewswire Apr 30, 2025, 5:42:04 PM.

The FDA on Tuesday held a panel discussion on the alleged risks of talcum powder. Talc, an anti-caking agent that is mined from rock, is prevalent in food and pharmaceutical products.

What to know about the effort to get rid of artificial food dyes 04:06. The U.S. Food and Drug Administration announced Friday it has approved the use of three color additives from natural sources ...

It's made in a way that allows for a lower dose — a fifth of the dose of its current COVID-19 vaccine, Spikevax — by refining its immune target.The approval “adds an important new tool to ...

The U.S. Food and Drug Administration on Wednesday approved Johnson & Johnson's drug to treat a type of muscle-weakening disorder, which is expected to bring in blockbuster revenues and drive growth.

FDA Approves New Long-Term Treatment for Myasthenia Gravis. Written by Joyani Das. 3 min read. May 2, 2025 ... according to a news release from Johnson and Johnson, the drug’s maker.

(RTTNews) - Satsuma Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration has approved a 505(b)(2) New Drug Application (NDA) for Atzumi(dihydroergotamine (DHE)) nasal powder ...

RFK Jr. previously said he wants to phase out petroleum-based dyes. The U.S. Food and Drug Administration (FDA) approved on Friday additional color additives from natural sources in line with the ...

The U.S. approved a new COVID-19 vaccine made by Moderna late Friday but with limits on who can use it — not a replacement for the company’s existing shot, but a second option.